Ofranergene obadenovec clinical trials
Also written VB-111.
How each study uses ofranergene obadenovec is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorizations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
6 studies that test it; most in 2010 (2)
| Year | Studies |
|---|---|
| 2007 | 1 |
| 2010 | 2 |
| 2015 | 1 |
| 2017 | 1 |
| 2020 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 5 · Other 1
Vascular Biogenics Ltd. operating as VBL Therapeutics (5) · Dana-Farber Cancer Institute (1)
Often tested with
Tested in the same studies.
Studies
Open first, then newest update. How each study uses ofranergene obadenovec is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 6
- VB-111 in Surgically Accessible Recurrent/Progressive GBMTerminatedPhase 2Dana-Farber Cancer InstituteNCT04406272Written as VB11
- A Study of VB-111 With Paclitaxel vs Paclitaxel for Treatment of Recurrent Platinum-Resistant Ovarian Cancer (OVAL)CompletedPhase 3Vascular Biogenics Ltd. operating as VBL TherapeuticsNCT03398655Written as VB-111 + Paclitaxel
- Single-Arm Open-Label Multicenter Study of VB-111 in Patients With Recurrent Glioblastoma MultiformeCompletedPhase 1/2Vascular Biogenics Ltd. operating as VBL TherapeuticsNCT01260506Written as VB-111
- Safety and Efficacy of VB-111 in Subjects With Advanced Differentiated Thyroid CancerCompletedPhase 2Vascular Biogenics Ltd. operating as VBL TherapeuticsNCT01229865Written as VB-111
- A Phase 3, Pivotal Trial of VB-111 Plus Bevacizumab vs. Bevacizumab in Patients With Recurrent Glioblastoma (GLOBE)CompletedPhase 3Vascular Biogenics Ltd. operating as VBL TherapeuticsNCT02511405Written as VB-111 + bevacizumab
- A Phase I Study to Assess the Safety and Distribution of VB-111 in Patients With Advanced Metastatic CancerStatus unknownPhase 1Vascular Biogenics Ltd. operating as VBL TherapeuticsNCT00559117Written as VB-111
Codes
What other systems call ofranergene obadenovec · ClinicalTrials.gg INT015108
- UNII (FDA) 5Q5PRH05GIOFRANERGENE OBADENOVECOne source FDA
- NCI Thesaurus C71539Ofranergene ObadenovecOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 5Q5PRH05GI | OFRANERGENE OBADENOVEC | One source FDA |
| NCI Thesaurus | C71539 | Ofranergene Obadenovec | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.